A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Principal Investigator
Lilian Gien, MD
Status
Terminated
Date Opened To Accrual
August 28 2018
Date Closed to Accrual
February 01 2021
Date of Study Termination
March 27 2024
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the objective tumor response (proportion of objective response by RECIST 1.1 criteria) of the combination of MK-3475 (pembrolizumab) and epacadostat in patients with recurrent or persistent clear cell carcinoma of the ovary
Patient Population
Women with recurrent or persistent clear cell carcinoma of the ovary.
Target Accrual
25
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.